EXAS - EXACT Sciences - Stock Price & Dividends

Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US30063P1057

Cancer, Screening, Diagnostic, Tests, DNA, Biomarkers, Oncotype

Exact Sciences Corporation is a pioneering healthcare company that specializes in developing and commercializing innovative cancer screening and diagnostic tests. With a strong presence in the United States and international markets, the company is dedicated to improving patient outcomes and enhancing the quality of life.

At the forefront of its product portfolio is Cologuard, a groundbreaking non-invasive stool-based DNA screening test. This revolutionary test detects DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer, providing patients with a convenient and accurate way to screen for this common and often preventable disease.

In addition to Cologuard, Exact Sciences offers a range of other diagnostic tests, including the Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, and Oncotype DX Colon Recurrence Score Test. These tests provide valuable insights for healthcare professionals, enabling them to make informed treatment decisions and improve patient care. The company also offers the OncoExTra Test, a comprehensive tumor profiling solution for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer.

Furthermore, Exact Sciences has expanded its offerings to include Covid-19 testing services, underscoring its commitment to addressing emerging healthcare needs. The company's research and development pipeline is focused on enhancing the performance characteristics of Cologuard and developing new blood and fluid-based tests, which will further expand its portfolio of innovative diagnostic solutions.

Exact Sciences has established strategic partnerships with esteemed institutions, including the MAYO Foundation for Medical Education and Research and Johns Hopkins University. These collaborations have facilitated the development of cutting-edge technologies and further solidified the company's position as a leader in the field of cancer diagnostics.

Founded in 1995, Exact Sciences Corporation is headquartered in Madison, Wisconsin, and has established itself as a driving force in the healthcare industry. For more information, please visit the company's website at https://www.exactsciences.com.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for EXAS - EXACT Sciences  - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for EXAS - EXACT Sciences  - Stock Price & Dividends

EXAS Stock Overview

Market Cap in USD 12,699m
Sector Healthcare
Industry Diagnostics & Research
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2001-02-01

EXAS Stock Ratings

Growth 5y -34.6
Fundamental -10.6
Dividend 0.00
Rel. Performance vs Sector -2.92
Analysts 4.61/5
Fair Price Momentum 67.87 USD
Fair Price DCF 4.31 USD

EXAS Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

EXAS Growth Ratios

Growth 12m 7.35%
Growth Correlation 12m -35.8%
Growth Correlation 3m 92%
CAGR 5y -6.06%
CAGR/Mean DD 5y -0.14
Sharpe Ratio 12m 0.05
Alpha vs SP500 12m -37.33
Beta vs SP500 5y weekly 1.33
ValueRay RSI 76.00
Volatility GJR Garch 1y 47.09%
Price / SMA 50 10.38%
Price / SMA 200 17.68%
Current Volume 1386.7k
Average Volume 20d 2381.6k

External Links for EXAS Stock

News
Wall Street JournalBenzingaYahoo Finance
Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of EXAS stocks?
As of October 11, 2024, the stock is trading at USD 69.34 with a total of 1,386,696 shares traded.
Over the past week, the price has changed by +4.41%, over one month by +18.77%, over three months by +52.97% and over the past year by +6.24%.
What are the forecast for EXAS stock price target?
According to ValueRays Forecast Model, EXAS EXACT Sciences will be worth about 75 in October 2025. The stock is currently trading at 69.34. This means that the stock has a potential upside of +8.21%.
Issuer Forecast Upside
Wallstreet Target Price 78.4 13.1
Analysts Target Price 106.4 53.4
ValueRay Target Price 75 8.21